Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) and Inotiv (NASDAQ:NOTV – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Ernexa Therapeutics and Inotiv, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ernexa Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Inotiv | 1 | 0 | 1 | 0 | 2.00 |
Inotiv has a consensus target price of $3.00, suggesting a potential upside of 393.91%. Given Inotiv’s stronger consensus rating and higher possible upside, analysts clearly believe Inotiv is more favorable than Ernexa Therapeutics.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ernexa Therapeutics | $580,000.00 | 17.73 | -$44.54 million | ($3.01) | -0.44 |
| Inotiv | $513.02 million | 0.04 | -$68.62 million | ($2.22) | -0.27 |
Ernexa Therapeutics has higher earnings, but lower revenue than Inotiv. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Inotiv, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Ernexa Therapeutics and Inotiv’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ernexa Therapeutics | N/A | -1,950.55% | -304.60% |
| Inotiv | -13.38% | -17.15% | -3.39% |
Volatility & Risk
Ernexa Therapeutics has a beta of 6.25, indicating that its share price is 525% more volatile than the S&P 500. Comparatively, Inotiv has a beta of 4.21, indicating that its share price is 321% more volatile than the S&P 500.
Insider & Institutional Ownership
70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 18.2% of Inotiv shares are held by institutional investors. 4.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 7.8% of Inotiv shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Inotiv beats Ernexa Therapeutics on 9 of the 14 factors compared between the two stocks.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About Inotiv
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
